Lund, Sweden — 30 June 2025 — During June 2025, 541,566 employee stock options in Camurus’ employee stock options program ESOP 2022/2026 have been exercised for subscription of the corresponding number of shares.
To ensure that the company can fulfill its commitments under the long-term incentive program for employees of the Camurus group as resolved by the 2025 Annual General Meeting (Performance Share Plan 2025/2028), Camurus issued 240,000 series C shares to Carnegie Investment Bank AB (publ) in June 2025. All series C shares have been repurchased by Camurus and converted into common shares in accordance with a conversion provision in the articles of association.
As a result of the exercises made under ESOP 2022/2026 and the series C share issue with subsequent repurchase and conversion made under Performance Share Plan 2025/2028, the number of shares and votes has increased by 781,566.
Prior to the exercises of employee stock options and the issue of series C shares, the total number of shares in Camurus amounted to 58,879,018 corresponding to 58,879,018 votes. As of 30 June 2025, the total number of shares in Camurus amounts to 59,660,584 corresponding to 59,660,584 votes.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
[email protected]
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
[email protected]
About Camurus
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn.
This information is information that Camurus AB is obliged to make public pursuant to Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act. The information was submitted for publication at 7:00 am CET on 30 June 2025.